Tyrosine Kinase Inhibitors Available for Chronic Myeloid Leukemia: Efficacy and Safety
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Tyrosine Kinase Inhibitors Available for Chronic Myeloid Leukemia: Efficacy and Safety
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 9, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2019-07-03
DOI
10.3389/fonc.2019.00603
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Renal dysfunction and anemia associated with long-term imatinib treatment in patients with chronic myelogenous leukemia
- (2019) Masatoshi Sakurai et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real‐life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart
- (2019) Giovanni Caocci et al. HEMATOLOGICAL ONCOLOGY
- Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice
- (2019) Carmen Fava et al. HAEMATOLOGICA
- How I Treat Chronic Myeloid Leukemia in Children and Adolescents
- (2019) Nobuko Hijiya et al. BLOOD
- Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice
- (2018) Massimo Breccia et al. ANNALS OF HEMATOLOGY
- Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial
- (2018) Jorge E. Cortes et al. BLOOD
- Early results of lower dose dasatinib (50 mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia
- (2018) Kiran Naqvi et al. CANCER
- Low-Dose Ponatinib in Intolerant Chronic Myeloid Leukemia Patients: A Safe and Effective Option
- (2018) Alessandra Iurlo et al. CLINICAL DRUG INVESTIGATION
- Considerations for Treatment-free Remission in Patients With Chronic Myeloid Leukemia: A Joint Patient–Physician Perspective
- (2018) Giuseppe Saglio et al. Clinical Lymphoma Myeloma & Leukemia
- Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase 1/2 study
- (2018) Carlo Gambacorti-Passerini et al. HAEMATOLOGICA
- Upfront low-dose ponatinib (15 mg/day) for multi-TKI resistant chronic myeloid leukemia
- (2018) Ayalew Tefferi HEMATOLOGICAL ONCOLOGY
- Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial
- (2018) Jorge E. Cortes et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: Results from the Phase IIIb ENESTswift study
- (2018) Devendra Hiwase et al. LEUKEMIA RESEARCH
- Excellent outcomes of 2G-TKI therapy after imatinib failure in chronic phase CML patients
- (2018) Mario Tiribelli et al. Oncotarget
- The new allosteric inhibitor asciminib is susceptible to resistance mediated by ABCB1 and ABCG2 overexpression in vitro
- (2018) Laura N. Eadie et al. Oncotarget
- Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase 1/2 study
- (2018) Carlo Gambacorti-Passerini et al. HAEMATOLOGICA
- Benefits and risks of ponatinib versus bosutinib following treatment failure of two prior tyrosine kinase inhibitors in patients with chronic phase chronic myeloid leukemia: a matching-adjusted indirect comparison
- (2018) Moshe Yair Levy et al. CURRENT MEDICAL RESEARCH AND OPINION
- Ponatinib evaluation and safety in real-life chronic myelogenous leukemia patients failing more than two tyrosine kinase inhibitors: The PEARL observational study
- (2018) Maël Heiblig et al. EXPERIMENTAL HEMATOLOGY
- Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia
- (2018) Timothy P. Hughes et al. HAEMATOLOGICA
- Cross-intolerance with bosutinib after prior tyrosine kinase inhibitors (TKIs) in patients (pts) with Philadelphia chromosome–positive (Ph+) leukemia: Phase 1/2 study update.
- (2018) Carlo Gambacorti-Passerini et al. JOURNAL OF CLINICAL ONCOLOGY
- Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1
- (2018) Joseph Schoepfer et al. JOURNAL OF MEDICINAL CHEMISTRY
- Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology
- (2018) Jerald P. Radich et al. Journal of the National Comprehensive Cancer Network
- Treatment‐free remission with first‐ and second‐generation tyrosine kinase inhibitors
- (2018) Jorge Cortes et al. AMERICAN JOURNAL OF HEMATOLOGY
- Safety and efficacy of bosutinib in fourth-line therapy of chronic myeloid leukemia patients
- (2018) Valentín García-Gutiérrez et al. ANNALS OF HEMATOLOGY
- Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2018) A Hochhaus et al. ANNALS OF ONCOLOGY
- Ponatinib induces a sustained deep molecular response in a chronic myeloid leukaemia patient with an early relapse with a T315I mutation following allogeneic hematopoietic stem cell transplantation: a case report
- (2018) Nuno Cerveira et al. BMC CANCER
- Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a population-based study
- (2017) Jason Weatherald et al. EUROPEAN RESPIRATORY JOURNAL
- Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results
- (2017) T P Hughes et al. LEUKEMIA
- Treatment-free remission in chronic myeloid leukemia: floating between expectation and evidence
- (2017) M Baccarani LEUKEMIA
- Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia
- (2017) Andreas Hochhaus et al. NEW ENGLAND JOURNAL OF MEDICINE
- Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib
- (2016) Jorge E. Cortes et al. AMERICAN JOURNAL OF HEMATOLOGY
- Long-term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosome-positive leukemias treated with bosutinib
- (2016) Jorge E. Cortes et al. AMERICAN JOURNAL OF HEMATOLOGY
- Analysis of 2013 European LeukaemiaNet (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcomes
- (2016) Preetesh Jain et al. BRITISH JOURNAL OF HAEMATOLOGY
- Evaluating the Impact of a Switch to Nilotinib on Imatinib-Related Chronic Low-Grade Adverse Events in Patients With CML-CP: The ENRICH Study
- (2016) Jorge E. Cortes et al. Clinical Lymphoma Myeloma & Leukemia
- Chronic myeloid leukemia: reminiscences and dreams
- (2016) T. I. Mughal et al. HAEMATOLOGICA
- Clinical efficacy and safety of high-dose imatinib for chronic myeloid leukemia patients: An updated meta-analysis
- (2016) Peng Wang et al. Journal of Cancer Research and Therapeutics
- Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial
- (2016) Jorge E. Cortes et al. JOURNAL OF CLINICAL ONCOLOGY
- Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial
- (2016) A Hochhaus et al. LEUKEMIA
- European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia
- (2016) J L Steegmann et al. LEUKEMIA
- Early molecular response in chronic myeloid leukemia and halving time: Latest evidences
- (2016) Massimo Breccia et al. LEUKEMIA RESEARCH
- Chronic myeloid leukemia: reminiscences and dreams
- (2016) T. I. Mughal et al. HAEMATOLOGICA
- Switching to nilotinib versus imatinib dose escalation in patients with chronic myeloid leukaemia in chronic phase with suboptimal response to imatinib (LASOR): a randomised, open-label trial
- (2016) Jorge E Cortes et al. Lancet Haematology
- Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia
- (2015) G. Gugliotta et al. HAEMATOLOGICA
- Chronic myeloid leukaemia
- (2015) Jane F Apperley LANCET
- Comparative efficacy of tyrosine kinase inhibitor treatments in the third-line setting, for chronic-phase chronic myelogenous leukemia after failure of second-generation tyrosine kinase inhibitors
- (2015) J.H. Lipton et al. LEUKEMIA RESEARCH
- Effects of first- and second-generation tyrosine kinase inhibitor therapy on glucose and lipid metabolism in chronic myeloid leukemia patients: a real clinical problem?
- (2015) Alessandra Iurlo et al. Oncotarget
- Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia
- (2015) G. Gugliotta et al. HAEMATOLOGICA
- Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials
- (2015) Koji Sasaki et al. Lancet Haematology
- First-line treatment of 102 chronic myeloid leukemia patients with imatinib: A long-term single institution analysis
- (2014) Ilaria Viganò et al. AMERICAN JOURNAL OF HEMATOLOGY
- Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study
- (2014) N. P. Shah et al. BLOOD
- Improved tolerability by a modified intermittent treatment schedule of dasatinib for patients with chronic myeloid leukemia resistant or intolerant to imatinib
- (2013) Paul La Rosée et al. ANNALS OF HEMATOLOGY
- European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
- (2013) M. Baccarani et al. BLOOD
- A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias
- (2013) J.E. Cortes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Impact of comorbidities on the treatment of chronic myeloid leukemia with tyrosine-kinase inhibitors
- (2013) Gabriele Gugliotta et al. Expert Review of Hematology
- Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure
- (2012) H. J. Khoury et al. BLOOD
- Pulmonary Arterial Hypertension in Patients Treated by Dasatinib
- (2012) David Montani et al. CIRCULATION
- Bosutinib Versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results From the BELA Trial
- (2012) Jorge E. Cortes et al. JOURNAL OF CLINICAL ONCOLOGY
- Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study
- (2012) F J Giles et al. LEUKEMIA
- Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib
- (2011) J. E. Cortes et al. BLOOD
- Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib
- (2011) J. E. Cortes et al. BLOOD
- Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)
- (2011) H. M. Kantarjian et al. BLOOD
- Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial
- (2011) Hagop M Kantarjian et al. LANCET ONCOLOGY
- Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy
- (2010) F J Giles et al. LEUKEMIA
- Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
- (2010) Giuseppe Saglio et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia
- (2009) G. Rosti et al. BLOOD
- Nilotinib As Front-Line Treatment for Patients With Chronic Myeloid Leukemia in Early Chronic Phase
- (2009) Jorge E. Cortes et al. JOURNAL OF CLINICAL ONCOLOGY
- Results of Dasatinib Therapy in Patients With Early Chronic-Phase Chronic Myeloid Leukemia
- (2009) Jorge E. Cortes et al. JOURNAL OF CLINICAL ONCOLOGY
- Chronic myeloid leukemia in Asia
- (2008) Wing Y. Au et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started